AstraZeneca

200 articles with AstraZeneca

• TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma

  12/17/2021

  AstraZeneca and Amgen’s TEZSPIRE (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

• EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study

  12/16/2021

  AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.

• Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy

  12/14/2021

  Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).

• FDA Issues Emergency Use Authorization For Astrazeneca's Evusheld™ (Tixagevimab Co-packaged With Cilgavimab), The First Antibody Therapy Authorized In The U.S. For Pre-exposure Prophylaxis Of COVID-19

  12/10/2021

  Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab and cilgavimab, together denoting the first long-acting antibody combination authorized for emergency use by the U.S. Food and Drug Administration (FDA) for pre-exposure prevention of COVID-19.

• EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19

  12/9/2021

  AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected to become available very soon.

• Datopotamab Deruxtecan Continues to Show Promising Durable Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer

  12/7/2021

  New data from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd), continue to show encouraging durable tumor response and disease control in patients with metastatic triple negative breast cancer (TNBC) with disease progression following standard treatment.

• AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care

  12/3/2021

  AstraZeneca will underscore its ambition to redefine care with new data from across its portfolio of innovative medicines at the 2021 San Antonio Breast Cancer Symposium (SABCS) December 7-10, 2021.

• LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer

  11/30/2021

  LYNPARZA ® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer.

• FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review

  11/30/2021

  FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA ® (olaparib) as Adjuvant Treatment in BRCA -Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review.

• NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects, in Collaboration with AstraZeneca

  11/11/2021

  The National Comprehensive Cancer Network's Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer.

• AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021

  11/5/2021

  AstraZeneca will present new data underscoring its commitment to transforming hematologic cancer care at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, December 11 to 14, 2021.

• Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics

  11/3/2021

  Integral Molecular, an industry leader in developing antibodies against membrane proteins, announced that it entered into an exclusive worldwide antibody license agreement with AstraZeneca to develop therapeutics for multiple cancers.

• SAGA Diagnostics enters into an assay development agreement with AstraZeneca

  11/2/2021

  SAGA Diagnostics AB has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca (LSE/STO/Nasdaq: AZN). 

• SAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment

  11/1/2021

  New subgroup analyses from the TULIP Phase III clinical trial program showed SAPHNELO, a first-in-class type I interferon antagonist, in addition to standard therapy, resulted in a greater reduction in systemic lupus erythematosus disease activity regardless of disease duration, standard therapy type and prior treatment, compared to standard therapy alone.

• AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities

  11/1/2021

  AstraZeneca is proud to announce contributions to 30 nonprofit, community-based organizations nationwide through the ACT on Health Equity: Community Solutions Challenge.

• Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer

  10/25/2021

  Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA ® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer

• Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis

  10/8/2021

  Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE).

• AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US

  10/5/2021

  Filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic COVID-19 with long-acting antibody combination (non-vaccine)

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens

  10/4/2021

  ENHERTU ® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens

• AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases

  9/27/2021

  AZD7442 long-acting antibody combination Phase III PROVENT trial prevention data to be presented in late-breaker session